{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:14:04Z","timestamp":1789013644421,"version":"build-2803163510"},"reference-count":14,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,4,10]],"date-time":"2014-04-10T00:00:00Z","timestamp":1397088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2014,6]]},"abstract":"<jats:p>It is unclear if patients with CML treated with imatinib who fail to achieve <jats:italic>BCR\/ABL<\/jats:italic> transcript levels &lt;10%<jats:sup>IS<\/jats:sup> at 3 months i.e. an early molecular response (EMR) have a better prognosis if they achieve a response by 6 months. We reviewed 320 patients with chronic myeloid leukemia (CML) in chronic phase receiving Imatinib therapy with 3 and 6 month <jats:italic>BCR\/ABL<\/jats:italic> transcript levels available, and divided them into four groups. Group I (achieved an EMR at 3 months), Group II (did not achieve an EMR at 3 months, but achieved a transcript level of &lt;1% at 6 months), Group III (did not achieve an EMR at 3 months, then at 6 months achieved a level between 1% and 10%) and Group IV (failed to achieve a response at 3 and 6 months). Compared to Group I, Group IV showed significantly worse freedom from treatment failure (FTF; 93.1% vs 69.0%, <jats:italic>P<\/jats:italic> &lt; 0.001), progression free survival (97.7% vs 77.3%, <jats:italic>P<\/jats:italic> &lt; 0.001) and overall survival (98.3% vs 78.9%, <jats:italic>P<\/jats:italic> &lt; 0.001). While, group III showed inferior PFS (98.3% vs 90.4%, <jats:italic>P<\/jats:italic> = 0.013) and OS (97.7% vs 90.4%, <jats:italic>P<\/jats:italic> = 0.037), but no difference in FTF (93.1% vs 92.0%, <jats:italic>P<\/jats:italic> = 0.520). There were no significant differences between Groups I and II. A <jats:italic>BCR\/ABL<\/jats:italic> transcript level at 6 months can identify a \u201cgood\u2010risk\u201d subgroup among patients who fail to achieve an EMR on Imatinib therapy for CML.Am. J. Hematol. 89:626\u2013632, 2014. \u00a9 2014 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.23707","type":"journal-article","created":{"date-parts":[[2014,3,12]],"date-time":"2014-03-12T09:41:40Z","timestamp":1394617300000},"page":"626-632","source":"Crossref","is-referenced-by-count":31,"title":["<i>BCR\/ABL<\/i> level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase"],"prefix":"10.1002","volume":"89","author":[{"given":"Dennis (Dong Hwan)","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Hematology Princess Margaret Hospital, University Health Network, University of Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Hamad","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology Princess Margaret Hospital, University Health Network, University of Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Gi","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology Princess Margaret Hospital, University Health Network, University of Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Kamel\u2010Reid","sequence":"additional","affiliation":[{"name":"Department of Pathology Toronto General Hospital, University Health Network, University of Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Lipton","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology Princess Margaret Hospital, University Health Network, University of Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,4,10]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.6565"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.85"},{"key":"e_1_2_6_4_1","first-page":"2767","article-title":"Dasatinib and imatinib\u2010induced reductions in BCR\u2010ABL transcript levels below 10% at 3 months are associated with improved responses in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP): Analysis of molecular response kinetics in the DASISION trial","volume":"118","author":"Hochhaus A","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.85"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12187"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030513"},{"key":"e_1_2_6_10_1","first-page":"2167","article-title":"Treatment of philadelphia chromosome\u2010positive, accelerated\u2010phase chronic myelogenous leukemia with imatinib mesylate","volume":"8","author":"Kantarjian HM","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21850"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.1.3.391"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244"},{"key":"e_1_2_6_15_1","first-page":"451","article-title":"Upfront imatinib therapy in CML patients with rapid switching to nilotinib for failure to achieve molecular targets or intolerance achieves high overall rates of molecular response and a low risk of progression\u2014An update of the TIDEL\u2010II trial","volume":"118","author":"Yeung DT","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23707","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23707","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T03:09:54Z","timestamp":1696648194000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,10]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["10.1002\/ajh.23707"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23707","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,10]]}}}